<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: following additional risks", fill: "#e4717a"},
{source: "1: following additional risks", target: "1: uncertainties", fill: "#e4717a"},
{source: "1: uncertainties", target: "1: financial condition", fill: "#e4717a"},
{source: "1: financial condition", target: "1: operations", fill: "#e4717a"},
{source: "1: following additional risks", target: "5: medication", fill: "#e32636"},
{source: "5: medication", target: "5: dispensing systems", fill: "#e32636"},
{source: "5: dispensing systems", target: "5: services would reduce", fill: "#e32636"},
{source: "5: medication", target: "7: healthcare facilities still use traditional approaches", fill: "#918151"},
{source: "7: healthcare facilities still use traditional approaches", target: "7: automated methods", fill: "#918151"},
{source: "7: automated methods", target: "7: medication", fill: "#918151"},
{source: "7: medication", target: "7: supply dispensing", fill: "#918151"},
{source: "7: supply dispensing", target: "7: management", fill: "#918151"},
{source: "7: healthcare facilities still use traditional approaches", target: "12: expenditures by", fill: "#ffbcd9"},
{source: "12: expenditures by", target: "12: facilities particularly", fill: "#ffbcd9"},
{source: "12: facilities particularly", target: "12: significant customers could decrease demand", fill: "#ffbcd9"},
{source: "12: significant customers could decrease demand", target: "12: medication", fill: "#ffbcd9"},
{source: "12: medication", target: "12: supply dispensing systems", fill: "#ffbcd9"},
{source: "12: expenditures by", target: "13: cannot assure", fill: "#ff2800"},
{source: "13: cannot assure", target: "13: will continue", fill: "#ff2800"},
{source: "13: will continue", target: "13: medication", fill: "#ff2800"},
{source: "13: medication", target: "13: supply dispensing systems", fill: "#ff2800"},
{source: "13: supply dispensing systems", target: "13: market acceptance", fill: "#ff2800"},
{source: "13: market acceptance", target: "13: such systems will", fill: "#ff2800"},
{source: "13: cannot assure", target: "14: installations", fill: "#465945"},
{source: "14: installations", target: "14: recognition", fill: "#465945"},
{source: "14: recognition", target: "14: revenue associated with", fill: "#465945"},
{source: "14: revenue associated with", target: "14: medication", fill: "#465945"},
{source: "14: medication", target: "14: supply dispensing systems", fill: "#465945"},
{source: "14: supply dispensing systems", target: "14: competitive position", fill: "#465945"},
{source: "14: competitive position", target: "14: operations", fill: "#465945"},
{source: "14: operations", target: "14: financial condition could", fill: "#465945"},
{source: "14: installations", target: "28: increased competition", fill: "#4f666a"},
{source: "28: increased competition", target: "28: from current", fill: "#4f666a"},
{source: "28: from current", target: "28: future competitors", fill: "#4f666a"},
{source: "28: future competitors", target: "28: significantly greater", fill: "#4f666a"},
{source: "28: significantly greater", target: "28: financial technical marketing", fill: "#4f666a"},
{source: "28: financial technical marketing", target: "28: resources than", fill: "#4f666a"},
{source: "28: increased competition", target: "29: direct competitors", fill: "#195905"},
{source: "29: direct competitors", target: "29: medication management", fill: "#195905"},
{source: "29: medication management", target: "29: supply chain solutions", fill: "#195905"},
{source: "29: supply chain solutions", target: "29: Pyxis Corporation ", fill: "#195905"},
{source: "29: Pyxis Corporation ", target: "29: of Cardinal Health Inc", fill: "#195905"},
{source: "29: direct competitors", target: "34: With ", fill: "#f64a8a"},
{source: "34: With ", target: "34: acquisition", fill: "#f64a8a"},
{source: "34: acquisition", target: "34: automated pharmacy storage", fill: "#f64a8a"},
{source: "34: automated pharmacy storage", target: "34: retrieval system", fill: "#f64a8a"},
{source: "34: retrieval system", target: "34: of an SafetyMed ", fill: "#f64a8a"},
{source: "34: of an SafetyMed ", target: "34: companies into", fill: "#f64a8a"},
{source: "34: companies into", target: "34: automated dispensing systems market space", fill: "#f64a8a"},
{source: "34: automated dispensing systems market space", target: "34: gained additional", fill: "#f64a8a"},
{source: "34: gained additional", target: "34: competitors", fill: "#f64a8a"},
{source: "34: With ", target: "START_HERE", fill: "#f64a8a"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Diversified Support Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lithium_(medication)">Lithium (medication)</a></td>
      <td>Certain lithium compounds, also known as lithium salts, are used as psychiatric medication, primarily for bipolar disorder and for major depressive disorder that does not improve following the use of antidepressants. In these disorders, it sometimes reduces the risk of suicide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Oxytocin_(medication)">Oxytocin (medication)</a></td>
      <td>Synthetic oxytocin, sold under the brand name Pitocin among others, is a medication made from the peptide oxytocin. As a medication, it is used to cause contraction of the uterus to start labor, increase the speed of labor, and to stop bleeding following delivery.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Antimalarial_medication">Antimalarial medication</a></td>
      <td>Antimalarial medications or simply antimalarials are a type of antiparasitic chemical agent, often naturally derived, that can be used to treat or to prevent malaria, in the latter case, most often aiming at two susceptible target groups, young children and pregnant women. As of 2018, modern treatments, including for severe malaria, continued to depend on therapies deriving historically from quinine and artesunate, both parenteral (injectable) drugs, expanding from there into the many classes of available modern drugs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Testosterone_(medication)">Testosterone (medication)</a></td>
      <td>Testosterone (T) is a medication and naturally occurring steroid hormone. It is used to treat male hypogonadism, gender dysphoria, and certain types of breast cancer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Insulin_(medication)">Insulin (medication)</a></td>
      <td>As a medication, insulin is any pharmaceutical preparation of the protein hormone insulin that is used to treat high blood glucose. Such conditions include type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hibar_Systems">Hibar Systems</a></td>
      <td>Hibar Systems Ltd was a Canadian manufacturer of automated, precision liquid dispensing and filling systems. \nHibar was started in 1974 when German-born Canadian engineer Heinz Barall developed a prototype of a precision metering pump that would dispense a small, precise amount (two microlitres) of electrolytes into button cell batteries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacist">Pharmacist</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Separation_of_prescribing_and_dispensing">Separation of prescribing and dispensing</a></td>
      <td>Separation of prescribing and dispensing, also called dispensing separation, is a practice in medicine and pharmacy in which the physician who provides a medical prescription is independent from the  pharmacist who provides the prescription drug.\nIn the Western world there are centuries of tradition for separating pharmacists from physicians.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automated_dispensing_cabinet">Automated dispensing cabinet</a></td>
      <td>An automated dispensing cabinet (ADC) is a computerized medicine cabinet for hospitals and healthcare settings. ADCs allow medications to be stored and dispensed near the point of care while controlling and tracking drug distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy">Pharmacy</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Water_dispenser">Water dispenser</a></td>
      <td>A water dispenser, known as water cooler (if used for cooling only), is a machine that cools or heats up and dispenses water with a refrigeration unit. It is commonly located near the restroom due to closer access to plumbing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automatic_lubrication_system">Automatic lubrication system</a></td>
      <td>An Automatic Lubrication System (ALS), sometimes referred to as a Centralized Lubrication System (CLS),is a system that delivers controlled amounts of lubricant to multiple locations on a machine while the machine is operating.  Even though these systems are usually fully automated, a system that requires a manual pump or button activation is still identified as a centralized lubrication system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Oxygen_mask">Oxygen mask</a></td>
      <td>An oxygen mask provides a method to transfer breathing oxygen gas from a storage tank to the lungs. Oxygen masks may cover only the nose and mouth (oral nasal mask) or the entire face (full-face mask).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hydrant">Hydrant</a></td>
      <td>In chemistry, a hydrate is a substance that contains water or its constituent elements. The chemical state of the water varies widely between different classes of hydrates, some of which were so labeled before their chemical structure was understood.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2011_military_intervention_in_Libya">2011 military intervention in Libya</a></td>
      <td>On 19 March 2011, a multi-state NATO-led coalition began a military intervention in Libya, to implement United Nations Security Council Resolution 1973, in response to events during the First Libyan Civil War. With ten votes in favour and five abstentions, the UN Security Council's intent was to have "an immediate ceasefire in Libya, including an end to the current attacks against civilians, which it said might constitute "crimes against humanity" ...</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tourism_in_Abkhazia">Tourism in Abkhazia</a></td>
      <td>Tourism in Abkhazia is possible under Georgian law for foreigners entering the occupied territory from Georgia, although Georgia cannot assure the safety inside disputed territory.\nHowever, the Abkazian beaches on the Black Sea continue to be accessible for tourists coming from the Russian side of the Abkhazia–Russia border which is not under Georgian control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_license">Medical license</a></td>
      <td>A medical license is an occupational license that permits a person to legally practice medicine. In most countries, a person must have a medical license bestowed either by a specified government-approved professional association or a government agency before he or she can practice medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitive_advantage">Competitive advantage</a></td>
      <td>In business, a competitive advantage is the attribute that allows an organization to outperform its competitors.\nA competitive advantage may include access to natural resources, such as high-grade ores or a low-cost power source, highly skilled labor, geographic location, high entry barriers, and access to new technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>OMNICELL INC /CA/      ITEM 1A        RISK FACTORS       We have identified the <font color="blue">following <font color="blue">additional</font> risks</font> and <font color="blue">uncertainties</font> that may     have a material adverse effect on our business, <font color="blue">financial condition</font> or     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not     <font color="blue">presently known</font> to us or that we currently believe are <font color="blue">immaterial may also</font>     <font color="blue"><font color="blue">significant</font>ly impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of these risks occur,     our business, results of <font color="blue">operations</font> or <font color="blue">financial condition</font> could suffer and     the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> could decline</font></td>
    </tr>
    <tr>
      <td>11     ______________________________________________________________________       Any reduction in the demand for or adoption of our <font color="blue">medication</font> and supply     <font color="blue">dispensing systems</font> and related <font color="blue">services would reduce</font> our revenues</td>
    </tr>
    <tr>
      <td>Our <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> represent only one approach to     managing the <font color="blue">distribution</font> of <font color="blue">pharmaceuticals</font> and <font color="blue">supplies at healthcare</font>     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Many healthcare <font color="blue">facilities</font> still use traditional approaches that     do  not  include <font color="blue">automated methods</font> of <font color="blue">medication</font> and <font color="blue">supply dispensing</font>     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>As  a  result,  we must <font color="blue">continuously</font> educate existing and     <font color="blue">prospective customers</font> about the <font color="blue">advantages</font> of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">medication</font>     and supply <font color="blue">dispensing systems</font> typically represent a <font color="blue">sizeable initial capital</font>     <font color="blue">expenditure</font> for <font color="blue">healthcare <font color="blue"><font color="blue">organization</font>s</font></font></td>
    </tr>
    <tr>
      <td>Changes in the budgets of these     <font color="blue"><font color="blue">organization</font>s</font> and the timing of <font color="blue">spending under</font> these budgets can have a     <font color="blue">significant</font> effect on the demand for our <font color="blue">medication</font> and <font color="blue">supply dispensing</font>     systems  and  related  services</td>
    </tr>
    <tr>
      <td>In addition, these budgets are often     <font color="blue">characterized by</font> limited resources and <font color="blue">conflicting spending priorities among</font>     <font color="blue">different departments</font></td>
    </tr>
    <tr>
      <td>Any decrease in <font color="blue">expenditure</font>s by these healthcare     <font color="blue">facilities</font>, <font color="blue">particularly</font> our <font color="blue">significant</font> customers, could decrease demand     for our <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> and related services and     reduce  our revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we <font color="blue">will continue</font> to be     successful in marketing our <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> or that     the  level  of <font color="blue">market acceptance</font> of <font color="blue">such systems will</font> be sufficient to     generate operating income</td>
    </tr>
    <tr>
      <td>If we experience delays in or loss of sales of, delays in <font color="blue"><font color="blue">installation</font>s</font> of,     or delays in the <font color="blue">recognition</font> of <font color="blue">revenue associated with</font> our <font color="blue">medication</font> and     supply <font color="blue">dispensing systems</font>, our <font color="blue"><font color="blue">competitive</font> position</font>, results of <font color="blue">operations</font>     and <font color="blue">financial condition</font> could be harmed</td>
    </tr>
    <tr>
      <td>The purchase of our <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> is often part     of a customer’s larger initiative to re-engineer its pharmacy, <font color="blue">distribution</font>     and  materials  <font color="blue">management</font>  systems</td>
    </tr>
    <tr>
      <td>As a result, the purchase of our     <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> has recently translated into larger     strategic purchases by customers that <font color="blue">frequently</font> require more complex and     stringent <font color="blue">contractual</font> <font color="blue"><font color="blue">requirement</font>s</font> and <font color="blue">generally</font> involve a <font color="blue">significant</font>     <font color="blue">commitment</font> of <font color="blue">management</font> attention and resources by <font color="blue">prospective customers</font></td>
    </tr>
    <tr>
      <td>These larger and more <font color="blue">complex deals often</font> require the input and approval of     many decision-makers, including pharmacy <font color="blue">directors</font>, materials managers,     nurse  managers,  financial  managers,  information  <font color="blue">systems managers</font>,     <font color="blue">administrators</font>,  lawyers  and boards of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>For these and other     reasons, the sales cycle associated with the sale of our <font color="blue">medication</font> and     supply <font color="blue">dispensing systems</font> is <font color="blue">often lengthy</font> and subject to a number of delays     over which we have little or no control</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will     not experience delays in the future</td>
    </tr>
    <tr>
      <td>A delay in, or loss of, sales of our     <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> could cause our operating results     to vary <font color="blue">significant</font>ly from quarter to quarter and <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>In addition, and in part as a result of the <font color="blue">aforementioned complexities</font>     inherent  in  <font color="blue">larger <font color="blue"><font color="blue">transaction</font>s</font></font>, our <font color="blue">average <font color="blue">installation</font> times</font> have     increased  for reasons that are <font color="blue">often outside</font> of our control</td>
    </tr>
    <tr>
      <td>Since we     recognize revenue only upon <font color="blue">installation</font> of our systems at a customer’s     site,  any  delay  in <font color="blue"><font color="blue">installation</font> by</font> our <font color="blue">customers could also</font> cause a     reduction in our revenue for a <font color="blue">given quarter</font></td>
    </tr>
    <tr>
      <td>In addition, the larger, more     <font color="blue">complex <font color="blue"><font color="blue">transaction</font>s</font> often</font> require us to include negotiated <font color="blue">contractual</font>     terms  that  have the effect of delaying revenue <font color="blue">recognition</font> under the     <font color="blue"><font color="blue">accounting</font> rules</font> that apply to us</td>
    </tr>
    <tr>
      <td>For all the above reasons, we believe that period-to-period comparisons of     our  operating  results  are  not <font color="blue">necessarily indicative</font> of our future     performance</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuation </font>in our quarterly operating results may cause our     stock price to decline</td>
    </tr>
    <tr>
      <td>The  <font color="blue">medication</font> <font color="blue">management</font> and <font color="blue"><font color="blue">supply <font color="blue">chain solutions</font></font> market</font> is highly     <font color="blue">competitive</font>  and  we may be unable to <font color="blue">compete successfully against new</font>     entrants and <font color="blue">established companies with greater resources</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">medication</font> <font color="blue">management</font> and <font color="blue"><font color="blue">supply <font color="blue">chain solutions</font></font> market</font> is intensely     <font color="blue">competitive</font> and is <font color="blue">characterized by</font> evolving <font color="blue">technologies</font> and industry     standards, frequent new product <font color="blue">introductions</font> and       12     ______________________________________________________________________       <font color="blue">dynamic customer</font> <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>We expect continued and <font color="blue">increased competition</font>     <font color="blue">from current</font> and <font color="blue">future <font color="blue"><font color="blue">competitor</font>s</font></font>, many of whom have <font color="blue">significant</font>ly greater     financial, technical, marketing and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>Our current     <font color="blue">direct <font color="blue"><font color="blue">competitor</font>s</font></font> in the <font color="blue">medication</font> <font color="blue">management</font> and <font color="blue">supply <font color="blue">chain solutions</font></font>     market include <font color="blue">Pyxis Corporation </font>(a division of Cardinal Health, Inc</td>
    </tr>
    <tr>
      <td>),     <font color="blue">McKesson Automation Inc</font></td>
    </tr>
    <tr>
      <td>(a business unit of McKesson Corporation) and     <font color="blue">AmerisourceBergen Corporation </font>(through its <font color="blue">acquisition</font> of MedSelect, Inc</td>
    </tr>
    <tr>
      <td>Pyxis Corporation, in particular, has a <font color="blue">significant</font>ly larger <font color="blue">installed base</font>     of  customers than we do and over the last few years has developed and     introduced to the market a <font color="blue">significant</font>ly larger number of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td><font color="blue">With     </font>the <font color="blue">acquisition</font> of an <font color="blue">automated pharmacy storage</font> and <font color="blue">retrieval system</font>, the     SafetyMed platform and ScanREQ, and with the entry of other <font color="blue">companies into</font>     the automated <font color="blue">dispensing systems</font> market space, we have <font color="blue">gained <font color="blue">additional</font></font>     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>They  include  AutoMed (an <font color="blue">AmerisourceBergen Corporation </font>    company), the <font color="blue">Baxter Medication Delivery </font>business of Baxter International     Inc, Care Fusion, Incorporated, Cerner Corporation, Eclipsys Corporation,     IDX Systems Corporation and Siemens Medical Solutions (a division of Siemens     AG)</td>
    </tr>
    <tr>
      <td>The <font color="blue">competitive</font> challenges we face in the <font color="blue">medication</font> <font color="blue">management</font> and supply     <font color="blue"><font color="blue">chain solutions</font> market</font> include, but are not limited to the following:       ·       our <font color="blue"><font color="blue">competitor</font>s</font> may develop, license or <font color="blue">incorporate new</font> or emerging     <font color="blue">technologies</font> or <font color="blue">devote greater resources</font> to the <font color="blue">development</font>, promotion and     sale of their products and services;       ·        certain  <font color="blue"><font color="blue">competitor</font>s</font> have greater name <font color="blue">recognition</font> and a more     extensive <font color="blue">installed base</font> of <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> or     other products and <font color="blue">services than</font> we do, and such <font color="blue">advantages</font> could be used to     increase their market share;       ·       other established or <font color="blue">emerging companies may enter</font> the <font color="blue">medication</font>     <font color="blue">management</font> and <font color="blue"><font color="blue">supply <font color="blue">chain solutions</font></font> market</font>;       ·       current and potential <font color="blue"><font color="blue">competitor</font>s</font> may make strategic <font color="blue">acquisition</font>s or     establish cooperative <font color="blue">relationships</font> among themselves or <font color="blue">with <font color="blue">third parties</font></font>,     including larger, more established healthcare supply companies, thereby     increasing their ability to develop and <font color="blue">offer products</font> and services to     address the needs of our <font color="blue">prospective customers</font>; and       ·       our <font color="blue"><font color="blue">competitor</font>s</font> may secure products and <font color="blue">services from suppliers on</font>     more favorable terms or <font color="blue">secure exclusive arrangements with suppliers</font> or     buyers that may impede the sales of our products and services</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Competitive </font>    </font><font color="blue">pressures could</font> result in <font color="blue">price reductions</font> of our products and services,     <font color="blue">fewer customer orders</font> and reduced gross margins, any of which <font color="blue">could harm</font> our     business</td>
    </tr>
    <tr>
      <td><font color="blue">Competitive </font><font color="blue">pressures could</font> result in <font color="blue">price reductions</font> of our products and     services, <font color="blue">fewer customer orders</font> and reduced gross margins, any of which     <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Our current and <font color="blue">potential customers may</font> have other business <font color="blue">relationships</font>     with our <font color="blue"><font color="blue">competitor</font>s</font> and consider those <font color="blue">relationships</font> when <font color="blue">deciding between</font>     our products and services and those of our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Many  of  our  <font color="blue"><font color="blue">competitor</font>s</font>  are large drug and medical-surgical supply     <font color="blue">distribution</font> companies that sell their <font color="blue">distribution</font> services to our current     and  potential customers</td>
    </tr>
    <tr>
      <td>As a result, if a customer is a <font color="blue">distribution</font>     customer  of  one of our <font color="blue"><font color="blue">competitor</font>s</font>, the customer may be motivated to     purchase  <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> or other automation     <font color="blue">solutions from</font> our <font color="blue">competitor</font> in order to maintain or enhance their business     <font color="blue">relationship with</font> that <font color="blue">competitor</font></td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________       The <font color="blue"><font color="blue">healthcare industry</font> faces financial constraints</font> and <font color="blue">consolidation</font> that     <font color="blue">could <font color="blue">adversely</font> affect</font> the demand for our products and services</td>
    </tr>
    <tr>
      <td>The  healthcare  industry has faced, and <font color="blue">will likely continue</font> to face,     <font color="blue">significant</font> financial constraints</td>
    </tr>
    <tr>
      <td>For example, the shift to <font color="blue">managed care</font> in     the 1990s put pressure on <font color="blue">healthcare <font color="blue"><font color="blue">organization</font>s</font></font> to <font color="blue">reduce costs</font>, and the     <font color="blue">Balanced Budget Act </font>of 1997 <font color="blue">significant</font>ly reduced Medicare <font color="blue">reimbursement</font> to     healthcare  <font color="blue"><font color="blue">organization</font>s</font></td>
    </tr>
    <tr>
      <td>Our  automation  <font color="blue">solutions often involve</font> a     <font color="blue">significant</font> financial <font color="blue">commitment</font> by our customers, and, as a result, our     ability  to  grow  our business is <font color="blue">largely <font color="blue">dependent</font> on</font> our customers’     information  <font color="blue">technology</font>  budgets</td>
    </tr>
    <tr>
      <td>To the extent healthcare information     <font color="blue">technology</font> spending declines or increases more slowly than we anticipate,     demand for our products and services would be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Many <font color="blue">healthcare providers</font> have <font color="blue">consolidated</font> to create <font color="blue">larger healthcare</font>     delivery <font color="blue"><font color="blue">organization</font>s</font> with greater market power</td>
    </tr>
    <tr>
      <td>If this <font color="blue">consolidation</font>     continues, it <font color="blue">could erode</font> our <font color="blue">customer base</font> and reduce the size of our     <font color="blue">target market</font></td>
    </tr>
    <tr>
      <td>In addition, the resulting <font color="blue"><font color="blue">organization</font>s</font> could have greater     bargaining power, which may lead to <font color="blue">price erosion</font></td>
    </tr>
    <tr>
      <td>If  we  are unable to maintain our <font color="blue">relationships</font> with group purchasing     <font color="blue"><font color="blue">organization</font>s</font> or other similar <font color="blue"><font color="blue">organization</font>s</font>, we may have <font color="blue"><font color="blue">difficult</font>y selling</font>     our products and services</td>
    </tr>
    <tr>
      <td>We have <font color="blue">agreements with various</font> group purchasing <font color="blue"><font color="blue">organization</font>s</font>, such as     AmeriNet, Inc,  Consorta, Inc, HealthTrust Purchasing Group, LP, MAGNET     Group,  Novation, LLC, and Premier, Inc, <font color="blue">which enable us</font> to sell more     readily  our  products  and services to <font color="blue">customers represented by</font> these     <font color="blue"><font color="blue">organization</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">relationships</font> with these <font color="blue"><font color="blue">organization</font>s</font> are <font color="blue">terminable at</font>     the convenience of <font color="blue">either party</font></td>
    </tr>
    <tr>
      <td>The loss of any of these <font color="blue">relationships</font>     <font color="blue">could impact</font> the breadth of our <font color="blue">customer base</font> and <font color="blue">could impair</font> our ability     to increase our revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that these <font color="blue"><font color="blue">organization</font>s</font> will     renew our contracts on similar terms, if at all, and they may choose to     terminate our contracts before they expire</td>
    </tr>
    <tr>
      <td>Our quarterly operating results may vary in the <font color="blue">future depending on</font> many     factors that include, but are not limited to, the following:       ·       the ability to <font color="blue">successfully install</font> our products on a <font color="blue">timely basis</font>     and meet other <font color="blue">contractual</font> obligations necessary to recognize revenue;       ·        the  size  and timing of orders for our <font color="blue">medication</font> and supply     <font color="blue">dispensing systems</font>, and their <font color="blue">installation</font> and <font color="blue">integration</font>;       ·       the <font color="blue">overall demand</font> for healthcare <font color="blue">medication</font> <font color="blue">management</font> and supply     <font color="blue">chain solutions</font>;       ·       changes in <font color="blue">pricing policies by us</font> or our <font color="blue"><font color="blue">competitor</font>s</font>;       ·       the number, timing and significance of <font color="blue">product enhancements</font> and new     <font color="blue">product <font color="blue"><font color="blue">announcement</font>s</font> by us</font> or our <font color="blue"><font color="blue">competitor</font>s</font>;       ·       the <font color="blue">relative proportions</font> of revenues we <font color="blue">derive from products</font> and     services;       ·       our customers’ budget cycles;       ·       changes in our operating expenses;       ·       the performance of our products;       ·       changes in our business strategy; and       ·        economic  and <font color="blue">political conditions</font>, including <font color="blue">fluctuations</font> in     <font color="blue">interest rates</font> and <font color="blue">tax increases</font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________       Due to the <font color="blue">foregoing factors</font>, our <font color="blue">quarterly revenues</font> and operating results     are <font color="blue">difficult</font> to predict and fluctuate, which in turn may cause the market     price of our stock to decline</td>
    </tr>
    <tr>
      <td>We have a history of operating losses and we <font color="blue">cannot assure</font> you that we will     maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>While we were <font color="blue">profitable with net income</font> of dlra10dtta6 million for the year     ended <font color="blue">December </font>31, 2004, we had a net loss of dlra2dtta1 million for the year     ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Therefore, we <font color="blue">cannot assure</font> you that we will be     profitable in the future</td>
    </tr>
    <tr>
      <td>Furthermore, we <font color="blue">cannot assure</font> you that if we again     become profitable we will be able to maintain or increase <font color="blue">profitability</font> in     the future on a quarterly or <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">market price</font> of our stock continues to be <font color="blue">highly volatile</font>, the value     of an <font color="blue">investment</font> in our <font color="blue"><font color="blue">common stock</font> may decline</font></td>
    </tr>
    <tr>
      <td>For the 12 months prior to <font color="blue">December </font>31, 2005, our <font color="blue">common stock</font> has traded     between dlra6dtta13 and dlra11dtta97 per share</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for shares of our     <font color="blue">common stock</font> has been and <font color="blue">may continue</font> to be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>In addition,     our <font color="blue"><font color="blue">announcement</font>s</font> or <font color="blue">external events may</font> have a <font color="blue">significant</font> <font color="blue">impact on</font> the     market  price of our stock</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">announcement</font>s</font> or <font color="blue">external events may</font>     include:       ·       our operating results;       ·       <font color="blue"><font color="blue">development</font>s</font> in our <font color="blue">relationships</font> with corporate customers;       ·       changes in the ratings of our <font color="blue">stock by securities analysts</font>;       ·       <font color="blue"><font color="blue">announcement</font>s</font> by us or our <font color="blue"><font color="blue">competitor</font>s</font> of <font color="blue">technological innovations</font>     or <font color="blue">new products</font>; or       ·       <font color="blue">general economic</font> and <font color="blue">market conditions</font></td>
    </tr>
    <tr>
      <td>Furthermore, the stock market as a whole from time to time has experienced     extreme price and volume <font color="blue">fluctuations</font>, which have <font color="blue">particularly</font> affected the     <font color="blue">market price</font>s for emerging companies</td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font> may     cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to <font color="blue">decline irrespective</font> of our     performance</td>
    </tr>
    <tr>
      <td>In addition, sales of substantial amounts of our <font color="blue">common stock</font>     in the <font color="blue">public market could lower</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Failure to maintain <font color="blue">effective</font> <font color="blue">internal control over financial</font> reporting in     <font color="blue">accordance</font> with Section 404 of the Sarbanes-Oxley Act of 2002 could have a     material adverse effect on our stock price</td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and     <font color="blue">regulations</font>  of  the  SEC require annual <font color="blue">management</font> <font color="blue"><font color="blue">assessment</font>s</font> of the     <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal control over financial</font> reporting and a report     by  our <font color="blue">in<font color="blue">dependent</font></font> <font color="blue">registered public <font color="blue">accounting</font> firm</font> attesting to and     reporting on these <font color="blue"><font color="blue">assessment</font>s</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain the adequacy of our     <font color="blue">internal control over financial</font> reporting, <font color="blue">as such standards</font> are modified,     supplemented or <font color="blue">amended from</font> time to time, we may not be able to ensure that     we can conclude on an <font color="blue">ongoing basis</font> that we have <font color="blue"><font color="blue">effective</font> internal control</font>     over  financial  reporting  in  <font color="blue">accordance</font>  with  Section 404  of  the     Sarbanes-Oxley Act of 2002 and the related rules and <font color="blue">regulations</font> of the SEC     For example, in 2004, we determined that we had a material weakness related     to  controls  over  the  review  of  <font color="blue">signed contracts prior</font> to revenue     <font color="blue">recognition</font></td>
    </tr>
    <tr>
      <td>Prior to year end 2004, we had interpreted our  internal     revenue <font color="blue">recognition</font> policy to require an enforceable contract as evidenced     by a signature from our customer</td>
    </tr>
    <tr>
      <td>During our year-end process we concluded     that our internal revenue <font color="blue">recognition</font> policy should have <font color="blue">been interpreted</font> to     require  both  the customer’s signature and our own <font color="blue">signature prior</font> to     recognizing revenue</td>
    </tr>
    <tr>
      <td>This material weakness in our <font color="blue">interpretation</font> of our     internal  revenue <font color="blue">recognition</font> policy arose from the lack of sufficient     understanding of our <font color="blue">internal policy</font></td>
    </tr>
    <tr>
      <td>As a result of this material weakness,     our <font color="blue">management</font> concluded that our <font color="blue">internal control over financial</font> reporting     and  our  <font color="blue">disclosure</font>  controls and procedures were not <font color="blue">effective</font> as of     <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>If we cannot in the <font color="blue">future favorably assess</font>, or our        15     ______________________________________________________________________       <font color="blue">in<font color="blue">dependent</font></font>  <font color="blue">registered public <font color="blue">accounting</font> firm</font> is unable to provide an     <font color="blue">unqualified attestation</font> report on our <font color="blue">assessment</font> of, the <font color="blue"><font color="blue">effective</font>ness</font> of     our <font color="blue">internal control over financial</font> reporting, <font color="blue">investor confidence</font> in the     <font color="blue">re<font color="blue">liability</font></font> of our financial reports may be <font color="blue">adversely</font> affected, which could     have a material adverse effect on our stock price</td>
    </tr>
    <tr>
      <td>We have <font color="blue">outstanding options</font> that have the potential to <font color="blue">dilute shareholder</font>     value and cause our <font color="blue">stock value</font> to decline</td>
    </tr>
    <tr>
      <td>We <font color="blue">frequently</font> <font color="blue">grant stock options</font> to our employees and other <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td>At     <font color="blue">December </font>31, 2005, we had <font color="blue">options outstanding</font> for 6cmam579cmam137 shares of our     <font color="blue">common stock</font> at option <font color="blue">exercise price</font>s ranging from dlra1dtta80 to dlra20dtta00 per     share</td>
    </tr>
    <tr>
      <td>If some or all of such shares are sold into the <font color="blue">public market over</font> a     short time period, the value of our stock may decline, as the <font color="blue">market may</font> not     be able to absorb those shares at the prevailing <font color="blue">market price</font>s</td>
    </tr>
    <tr>
      <td>Such sales     may also make it more <font color="blue">difficult</font> for us to <font color="blue">sell <font color="blue">equity securities</font></font> in the     <font color="blue">future on terms</font> that we deem acceptable</td>
    </tr>
    <tr>
      <td><font color="blue">Decreased </font><font color="blue"><font color="blue">effective</font>ness</font> of equity <font color="blue">compensation</font> could negatively impact our     ability to attract and retain employees, and a <font color="blue">modification</font> to our equity     <font color="blue">compensation</font>  strategy  or  recent  changes  in  <font color="blue">accounting</font> for equity     <font color="blue">compensation</font> <font color="blue">could <font color="blue">adversely</font> affect</font> our earnings</td>
    </tr>
    <tr>
      <td><font color="blue">Accounting </font>principles <font color="blue">generally</font> accepted in the <font color="blue">United States </font>are subject to     <font color="blue">interpretation</font> by the Financial <font color="blue">Accounting </font>Standards Board, or FASB, the     American Institute of Certified Public Accountants, the Public Company     <font color="blue">Accounting </font>Oversight Board, the Securities and Exchange Commission, and     various bodies formed to promulgate and interpret <font color="blue">appropriate</font> <font color="blue">accounting</font>     principles</td>
    </tr>
    <tr>
      <td>A change in these principles or <font color="blue">interpretation</font>s could have a     <font color="blue">significant</font> effect on our reported financial results, and <font color="blue">could affect</font> the     reporting of <font color="blue"><font color="blue">transaction</font>s</font> completed before the <font color="blue">implementation</font> of a new     <font color="blue">accounting</font> principle</td>
    </tr>
    <tr>
      <td>We currently account for stock options under <font color="blue">APB Opinion </font>Nodtta 25, “<font color="blue">Accounting </font>    for Stock Issued to Employees,” and, <font color="blue">accordingly</font>, we record <font color="blue">compensation</font>     expense  related  to  stock options if the current <font color="blue">market price</font> of the     <font color="blue">underlying stock exceeds</font> the <font color="blue">exercise price</font> of the <font color="blue">stock option on</font> the date     of grant</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, the FASB issued a revision of <font color="blue">Statement </font>of     Financial  <font color="blue">Accounting </font> Standards  Nodtta 123, “<font color="blue">Accounting </font>for Stock-Based     Compensation</td>
    </tr>
    <tr>
      <td>” The revision, “SFAS 123R—Share-Based Payment,” is <font color="blue">effective</font>     for reporting <font color="blue">periods beginning</font> after June 15, 2005</td>
    </tr>
    <tr>
      <td>On April 14, 2005, the     <font color="blue">Securities and Exchange Commission </font>adopted a <font color="blue">rule amendment</font> that delayed the     <font color="blue">compliance dates</font> for SFAS 123R such that we are now allowed to adopt the new     standard <font color="blue">no later than</font> January 1, 2006</td>
    </tr>
    <tr>
      <td>SFAS 123R supersedes <font color="blue">APB Opinion </font>25,     and will require companies to recognize <font color="blue">compensation</font>, using the fair-value     <font color="blue">based method</font>, for costs related to share-based payments including stock     options and <font color="blue">stock issued under</font> our <font color="blue">employee stock purchase</font> plans</td>
    </tr>
    <tr>
      <td>The impact of the adoption of SFAS 123R cannot be <font color="blue">predicted at</font> this time     because it <font color="blue">will <font color="blue">depend on</font> levels</font> of share-based payments granted in the     future</td>
    </tr>
    <tr>
      <td>However, valuation of <font color="blue">employee stock options under</font> SFAS 123R is     similar to SFAS 123, with minor exceptions</td>
    </tr>
    <tr>
      <td>The <font color="blue">impact on</font> the results of     <font color="blue">operations</font> and <font color="blue">earnings per</font> share had the Company adopted SFAS 123, is     described more fully in Note 1, “Organization and Summary of Significant     <font color="blue">Accounting </font>Policies</td>
    </tr>
    <tr>
      <td>” <font color="blue">The Company </font>expects that the adoption of SFAS 123R’s     <font color="blue">fair value method will</font> have a <font color="blue">significant</font> <font color="blue">impact on</font> the Company’s results of     <font color="blue">operations</font>, although it is not expected to have an <font color="blue">impact on</font> our overall     <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>SFAS 123R also requires the benefits of <font color="blue">tax deductions</font>     in excess of recognized <font color="blue">compensation</font> cost to be reported as a <font color="blue">financing cash</font>     flow,  <font color="blue">rather than as</font> an operating <font color="blue">cash flow as</font> required <font color="blue">under current</font>     literature</td>
    </tr>
    <tr>
      <td>This <font color="blue"><font color="blue">requirement</font> will reduce net</font> operating <font color="blue">cash flows</font> and     increase  net  financing  <font color="blue">cash flows</font> in periods after adoption</td>
    </tr>
    <tr>
      <td>We are     currently  evaluating the impact of this <font color="blue">statement on</font> our <font color="blue">consolidated</font>     <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>We  have  <font color="blue">historically</font>  used  stock  options and other forms of equity     <font color="blue">compensation</font> as key <font color="blue">components</font> of our employee <font color="blue">compensation</font> program in order     to align employees’ interests with the interests of our       16     ______________________________________________________________________       <font color="blue">stockholders</font>,  encourage  employee  retention, and provide <font color="blue">competitive</font>     <font color="blue">compensation</font> packages</td>
    </tr>
    <tr>
      <td>The changing <font color="blue">regulatory landscape could</font> make it more     <font color="blue">difficult</font> and less favorable for us to <font color="blue">grant stock options</font> to employees in     the future</td>
    </tr>
    <tr>
      <td>In light of these changes, we anticipate that we may modify our     equity <font color="blue">compensation</font> strategy to <font color="blue">emphasize equity <font color="blue">incentives</font></font> other than stock     options, including <font color="blue">increased use</font> of certain performance-related features</td>
    </tr>
    <tr>
      <td>If     employees believe that the <font color="blue">incentives</font> that they would receive under any such     <font color="blue">modified strategy</font> are <font color="blue">less attractive</font>, we may find it <font color="blue">difficult</font> to attract,     retain and <font color="blue">motivate employees</font></td>
    </tr>
    <tr>
      <td>To the extent that new <font color="blue">regulations</font> make it     more <font color="blue">difficult</font> or expensive to grant equity <font color="blue">instruments</font> to employees, we may     incur increased <font color="blue">compensation</font> costs, further change our equity <font color="blue">compensation</font>     strategy or find it <font color="blue">increasingly</font> <font color="blue">difficult</font> to attract, retain and motivate     employees, each of which could <font color="blue">materially</font> and <font color="blue">adversely</font> affect our business,     <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  may  not  be able to <font color="blue">successfully integrate</font> acquired <font color="blue">businesses</font> or     <font color="blue">technologies</font> into our existing business, <font color="blue">which could negatively impact</font> our     operating results</td>
    </tr>
    <tr>
      <td>As a part of our business strategy, during the past few years we acquired an     <font color="blue">automated pharmacy storage</font> and <font color="blue">retrieval system</font>, <font color="blue">the SafetyMed </font>platform, and     <font color="blue">SecureVault </font>and we may seek to acquire other <font color="blue">businesses</font>, <font color="blue">technologies</font> or     products in the future</td>
    </tr>
    <tr>
      <td>While we expect to <font color="blue">analyze carefully</font> all potential     <font color="blue"><font color="blue">transaction</font>s</font>  before <font color="blue">committing</font> to them, we <font color="blue">cannot assure</font> you that any     <font color="blue">transaction</font> that is completed will result in long-term benefits to us or our     <font color="blue">stockholders</font>, or that our <font color="blue">management</font> will be able to integrate or manage the     acquired business <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font><font color="blue">entail numerous risks</font>, including     <font color="blue">difficult</font>ies associated with the <font color="blue">integration</font> of <font color="blue">operations</font>, <font color="blue">technologies</font>,     products and personnel that, if realized, <font color="blue">could harm</font> our operating results</td>
    </tr>
    <tr>
      <td>Risks related to potential <font color="blue">acquisition</font>s include, but are not limited to:       ·        uncertain  <font color="blue">availability</font>  of  suitable <font color="blue">businesses</font>, products or     <font color="blue">technologies</font> for <font color="blue">acquisition</font> on terms acceptable to us;       ·       <font color="blue">difficult</font>ies in combining previously separate <font color="blue">businesses</font> into a     single unit;       ·       substantial diversion of <font color="blue">management</font>’s attention from day-to-day     business  when  evaluating  and negotiating such <font color="blue"><font color="blue">transaction</font>s</font> and then     <font color="blue">integrating</font> an acquired business;       ·       <font color="blue">discovery</font>, after <font color="blue">completion</font> of the <font color="blue">acquisition</font>, of <font color="blue">liabilities</font>     assumed  from the acquired business or of assets acquired that are not     realizable;       ·       failure to achieve anticipated <font color="blue">benefits such as cost savings</font> and     <font color="blue">revenue enhancements</font>;       ·       <font color="blue">difficult</font>ies related to <font color="blue">assimilating</font> the products of an acquired     business; and       ·       failure to understand and compete <font color="blue">effective</font>ly in markets in which we     have limited previous experience</td>
    </tr>
    <tr>
      <td>If our US <font color="blue"><font color="blue">government</font> customers</font> do not receive their <font color="blue">annual funding</font>, our     ability to recognize <font color="blue">revenues on future sales</font> to US <font color="blue"><font color="blue">government</font> customers</font>,     to sell our US <font color="blue"><font color="blue">government</font> <font color="blue">receivables</font></font> to third-party leasing companies or     to <font color="blue">collect payments on unsold <font color="blue">receivables</font> from</font> US <font color="blue"><font color="blue">government</font> customers</font>     could be impaired</td>
    </tr>
    <tr>
      <td>In our judgment     and <font color="blue">based on</font> our <font color="blue">history with</font> these <font color="blue">accounts</font>, we believe these <font color="blue">receivables</font>     are <font color="blue">collectible</font></td>
    </tr>
    <tr>
      <td>However, in the future, the failure of any of our US     <font color="blue">government</font>  customers to receive their <font color="blue">annual funding</font> <font color="blue">could impair</font> our     ability  to  sell  to  these  customers or to sell our US <font color="blue">government</font>     <font color="blue">receivables</font> to third-party leasing companies</td>
    </tr>
    <tr>
      <td>In addition, the ability to     collect payments on unsold <font color="blue">receivables</font> could be impaired and may result in a     write down of our unsold <font color="blue">receivables</font> to US <font color="blue"><font color="blue">government</font> customers</font></td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, the balance of our <font color="blue">unsold leases</font> to US <font color="blue">government</font>     customers was dlra3dtta6 million</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________       If we are unable to recruit and retain skilled and <font color="blue">motivated personnel</font>, our     <font color="blue"><font color="blue">competitive</font> position</font>, results of <font color="blue">operations</font> and <font color="blue">financial condition</font> could be     harmed</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">highly <font color="blue">dependent</font> upon</font> the <font color="blue">continuing contributions</font> of our key     <font color="blue">management</font>, sales, technical and <font color="blue"><font color="blue">engineering</font> staff</font></td>
    </tr>
    <tr>
      <td>We believe that our     <font color="blue"><font color="blue">future success will depend</font> upon</font> our ability to attract, train and retain     <font color="blue">highly skilled</font> and <font color="blue">motivated personnel</font></td>
    </tr>
    <tr>
      <td>As our <font color="blue">installed base</font> of <font color="blue">customers increases</font>, we <font color="blue">will also face</font>     <font color="blue"><font color="blue">additional</font> demands on</font> our <font color="blue">customer service</font> and <font color="blue">support personnel</font>, requiring     <font color="blue"><font color="blue">additional</font> resources</font> to meet these demands</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">difficult</font>y in     recruiting  qualified  personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for qualified technical,     <font color="blue">engineering</font>, managerial, sales, marketing, financial reporting and other     personnel can be intense and we <font color="blue">cannot assure</font> you that we will be successful     in attracting and retaining <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>have in the     <font color="blue">past attempted</font>, and may in the <font color="blue">future attempt</font>, to recruit our employees</td>
    </tr>
    <tr>
      <td>Failure to attract and retain key personnel <font color="blue">could harm</font> our <font color="blue">competitive</font>     position, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a limited number of suppliers for our <font color="blue">medication</font> and supply     <font color="blue">dispensing systems</font>, and our business may suffer if we are unable to obtain     an <font color="blue">adequate supply</font> of <font color="blue">components</font> and <font color="blue">equipment on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">production strategy</font> for our <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> is     to work closely with several key sub-assembly <font color="blue">manufacture</font>rs and equipment     providers and <font color="blue">utilize lower cost <font color="blue">manufacture</font>rs whenever possible</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>many of the <font color="blue">components</font> of our systems are <font color="blue">standardized</font> and <font color="blue">available from</font>     multiple sources, certain <font color="blue">components</font> or subsystems are <font color="blue">fabricated according</font>     to our <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>At any given point in time, we may only use a single     source of supply for certain <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Our failure to obtain <font color="blue">alternative</font>     vendors, if required, for any of the numerous <font color="blue">components</font> used to <font color="blue">manufacture</font>     our products would limit our ability to <font color="blue">manufacture</font> our products and could     harm our business</td>
    </tr>
    <tr>
      <td>In addition, any failure of a <font color="blue">maintenance contractor</font> to     perform adequately <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully integrate</font> our <font color="blue"><font color="blue">automation solutions</font> with</font> the     existing information systems of our customers, they may choose not to use     our products and services</td>
    </tr>
    <tr>
      <td>For healthcare <font color="blue">facilities</font> to <font color="blue">fully benefit from</font> our <font color="blue">automation solutions</font>,     our systems must integrate with their existing information systems</td>
    </tr>
    <tr>
      <td>This may     require substantial cooperation, <font color="blue">investment</font> and <font color="blue">coordination on</font> the part of     our customers</td>
    </tr>
    <tr>
      <td>There is little <font color="blue">uniformity</font> in the <font color="blue">systems currently used by</font>     our customers, which complicates the <font color="blue">integration</font> process</td>
    </tr>
    <tr>
      <td>If these systems     are not <font color="blue">successfully integrate</font>d, our <font color="blue">customers could choose</font> not to use or to     reduce their use of our <font color="blue">automation solutions</font>, which would harm our business</td>
    </tr>
    <tr>
      <td>Our failure to protect our <font color="blue"><font color="blue">intellectual</font> property rights could negatively</font>     affect our ability to compete</td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">success depends</font> in part on our ability to obtain patent     protection for <font color="blue">technology</font> and processes and our ability to preserve our     trademarks, copyrights and <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We have pursued patent protection     in  the <font color="blue">United States </font>and foreign <font color="blue">jurisdictions</font> for <font color="blue">technology</font> that we     believe to be <font color="blue">proprietary</font> and for <font color="blue">technology</font> that <font color="blue">offers us</font> a potential     <font color="blue">competitive</font> advantage for our products and we intend to continue to pursue     <font color="blue">such protection</font> in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">issued patents</font> relate to various features     of our <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font></td>
    </tr>
    <tr>
      <td>There can be no assurance     that we will file any <font color="blue">patent applications</font> in the future that any of our     <font color="blue">patent applications</font> will result in <font color="blue">issued patents</font> or that, if issued, such     patents  will  provide  <font color="blue">significant</font>  protection for our <font color="blue">technology</font> and     processes</td>
    </tr>
    <tr>
      <td>Furthermore, there can be no assurance that <font color="blue">others will</font> not     develop <font color="blue">technologies</font> that are similar or superior to our <font color="blue">technology</font> or that     <font color="blue">others will</font> not <font color="blue">design around</font> the patents we own</td>
    </tr>
    <tr>
      <td>All of our system software     is copyrighted and subject to the protection of <font color="blue">applicable copyright laws</font></td>
    </tr>
    <tr>
      <td>Despite our efforts to protect our <font color="blue">proprietary</font> rights, unauthorized parties     <font color="blue">may attempt</font> to <font color="blue">copy aspects</font> of our products or obtain and use information     that we regard as <font color="blue">proprietary</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       <font color="blue">Intellectual </font>property claims <font color="blue">against us</font> <font color="blue">could harm</font> our <font color="blue"><font color="blue">competitive</font> position</font>,     results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Although we have received no notice     alleging  <font color="blue">infringement</font>  from this <font color="blue">third party</font> to date, there can be no     assurance  that such <font color="blue">third party</font> will not assert an <font color="blue">infringement</font> claim     <font color="blue">against us</font> in the future</td>
    </tr>
    <tr>
      <td>Other than this patent, we do not believe that any     of our <font color="blue">products infringe upon</font> the <font color="blue">proprietary</font> rights of any <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In the future, <font color="blue">third parties</font> may claim that we have infringed upon their     <font color="blue">intellectual</font> property rights <font color="blue">with respect</font> to current or future products</td>
    </tr>
    <tr>
      <td>We     expect that <font color="blue">developers</font> of <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font> will be     <font color="blue">increasingly</font> subject to <font color="blue">infringement</font> claims as the number of products and     <font color="blue"><font color="blue">competitor</font>s</font> in our <font color="blue">industry grows</font> and the <font color="blue">functionality</font> of products in     <font color="blue">different industry segments overlaps</font></td>
    </tr>
    <tr>
      <td>We do not possess <font color="blue">special insurance</font>     that covers <font color="blue">intellectual</font> property <font color="blue">infringement</font> claims; however, such claims     may be <font color="blue">covered under</font> our <font color="blue">traditional <font color="blue">insurance policies</font></font></td>
    </tr>
    <tr>
      <td>These policies     contain terms, conditions and <font color="blue">exclusions</font> that make recovery for <font color="blue">intellectual</font>     <font color="blue">infringement</font> claims <font color="blue">difficult</font> to guarantee</td>
    </tr>
    <tr>
      <td>Any <font color="blue">infringement</font> claims, with or     without  merit,  could  be  time-consuming to defend, result in costly     litigation, divert <font color="blue">management</font>’s attention and resources, cause product     <font color="blue">shipment delays</font> or require us to <font color="blue">enter into royalty</font> or <font color="blue">licensing agreements</font></td>
    </tr>
    <tr>
      <td>These royalty or <font color="blue">licensing agreements</font>, if required, may not be <font color="blue">available on</font>     terms  acceptable  to  us, or at all, which <font color="blue">could harm</font> our <font color="blue">competitive</font>     position, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims <font color="blue">against us</font> <font color="blue">could harm</font> our <font color="blue"><font color="blue">competitive</font> position</font>,     results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our products provide <font color="blue">medication</font> <font color="blue">management</font> and <font color="blue">supply <font color="blue">chain solutions</font></font> for     the <font color="blue">healthcare industry</font></td>
    </tr>
    <tr>
      <td>Despite the presence of healthcare <font color="blue">professionals</font> as     <font color="blue">intermediaries</font> between our products and patients, if our <font color="blue">products fail</font> to     provide accurate and timely information or operate as designed, customers,     patients or their family members could assert claims <font color="blue">against us</font> for product     <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font><font color="blue">with respect</font> to     <font color="blue">liability</font> claims, <font color="blue">regardless</font> of its outcome, could result in substantial     cost to us, divert <font color="blue">management</font>’s attention from <font color="blue">operations</font> and decrease     <font color="blue">market acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>Although we have not experienced any     product <font color="blue">liability</font> claims to date, the sale and support of our products     entail  the  risk of product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>We possess a variety of     <font color="blue">insurance policies</font> that include coverage for general commercial <font color="blue">liability</font>     and <font color="blue">technology</font> errors and omissions <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">policies may</font>     not be adequate against product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>A successful claim brought     against  us,  or  any claim or <font color="blue">product recall</font> that results in negative     publicity  about  us,  <font color="blue">could harm</font> our <font color="blue"><font color="blue">competitive</font> position</font>, results of     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Changing </font>customer <font color="blue"><font color="blue">requirement</font>s</font> could decrease the demand for our products     and services</td>
    </tr>
    <tr>
      <td>The <font color="blue">medication</font> <font color="blue">management</font> and <font color="blue"><font color="blue">supply <font color="blue">chain solutions</font></font> market</font> is intensely     <font color="blue">competitive</font> and is <font color="blue">characterized by</font> evolving <font color="blue">technologies</font> and industry     standards,  frequent  new  product  <font color="blue">introductions</font> and <font color="blue">dynamic customer</font>     <font color="blue"><font color="blue">requirement</font>s</font> that may render <font color="blue"><font color="blue">existing products</font> obsolete</font> or less <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>As a result, our position in the <font color="blue">medication</font> <font color="blue">management</font> and supply chain     solutions  market <font color="blue">could erode</font> rapidly due to unforeseen changes in the     features and functions of competing products, as well as the <font color="blue">pricing models</font>     for <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will depend</font> in part upon our ability     to enhance our <font color="blue">existing products</font> and services and to develop and introduce     new  products and services to meet changing customer <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>The     process  of developing products and <font color="blue">services such as</font> those we offer is     <font color="blue">extremely complex</font> and is expected to become <font color="blue">increasingly</font> more complex and     expensive in the future as new <font color="blue">technologies</font> are introduced</td>
    </tr>
    <tr>
      <td>If we are unable     to enhance our <font color="blue">existing products</font> or develop <font color="blue">new products</font> to meet changing     customer <font color="blue"><font color="blue">requirement</font>s</font>, demand for our <font color="blue">products could decrease</font></td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       We may need <font color="blue"><font color="blue">additional</font> financing</font> in the future to meet our capital needs and     <font color="blue">such financing may</font> not be <font color="blue">available on</font> favorable terms and may be dilutive     to existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We  intend  to  continue  to expend substantial funds for research and     <font color="blue">development</font>  <font color="blue">activities</font>,  product  <font color="blue">development</font>, expansion of sales and     marketing  <font color="blue">activities</font> and the potential <font color="blue">acquisition</font> and <font color="blue">integration</font> of     <font color="blue">complementary products</font> and <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>As a consequence, in the future we     may need to seek <font color="blue"><font color="blue">additional</font> financing</font> to meet our working capital needs and     to finance capital <font color="blue">expenditure</font>s, as well as to fund <font color="blue">operations</font> or potential     <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>We may be unable to obtain any desired <font color="blue"><font color="blue">additional</font> financing</font> on     terms favorable to us, if at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not <font color="blue">available on</font>     acceptable terms, we may be unable to fund our expansion, successfully     develop  or <font color="blue">enhance products</font>, respond to <font color="blue">competitive</font> pressures or take     advantage of <font color="blue">acquisition</font> opportunities, any of <font color="blue">which could negatively affect</font>     our business</td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise <font color="blue">additional</font> funds through</font> the issuance of equity     securities, our <font color="blue">stockholders</font> will experience dilution of their ownership     interest</td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise <font color="blue">additional</font> funds by issuing debt</font>, we may be subject to     <font color="blue">limitations on</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have an <font color="blue">effective</font> “shelf” registration     <font color="blue">statement which enables us</font> to offer and sell, from time to time, up to a     <font color="blue">total dollar amount</font> of dlra100 million of our debt and <font color="blue">equity securities</font> in one     or more offerings, which could cause our <font color="blue">stockholders</font> to experience dilution     of their <font color="blue">ownership interest</font> and may cause our stock price to decline</td>
    </tr>
    <tr>
      <td>If our <font color="blue">new product solutions</font> do not achieve <font color="blue">market acceptance</font>, our sales and     operating results will be affected</td>
    </tr>
    <tr>
      <td>We market <font color="blue">new products</font>, <font color="blue">historically</font> added through <font color="blue">acquisition</font>s, which we     believe  are <font color="blue">competitive</font> in their <font color="blue">respective markets</font> and will meet the     demands of our customers</td>
    </tr>
    <tr>
      <td>Our ongoing business goals are <font color="blue">dependent</font> in part     <font color="blue">on customer acceptance</font> of these <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we     will be successful in marketing these products, that these <font color="blue">products will</font>     compete <font color="blue">effective</font>ly with similar <font color="blue">products sold by</font> our <font color="blue"><font color="blue">competitor</font>s</font> or that     the  level of <font color="blue">market acceptance</font> of <font color="blue">such products</font> will be sufficient to     generate expected revenues and <font color="blue">synergies with</font> our other products</td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">deployment</font>  of  these  new  products  typically require     <font color="blue">interoperability with</font> other Omnicell <font color="blue">products as well as with healthcare</font>     <font color="blue">facilities</font>’ existing information <font color="blue">management</font> systems</td>
    </tr>
    <tr>
      <td>If these <font color="blue">products fail</font>     to satisfy these <font color="blue">demanding technological objectives</font>, our <font color="blue">customers will</font> be     <font color="blue">dissatisfied</font> and we may be unable to <font color="blue">generate future sales</font></td>
    </tr>
    <tr>
      <td>Failure to     establish a <font color="blue">significant</font> base of customer references will <font color="blue">significant</font>ly     reduce our ability to sell these products to <font color="blue">additional</font> customers</td>
    </tr>
    <tr>
      <td>Some of our products incorporate <font color="blue">technologies</font> owned by <font color="blue">third parties</font> that     are licensed to us for use, <font color="blue">modification</font> and/or <font color="blue">distribution</font>, including but     not limited to certain <font color="blue">Commerce One </font><font color="blue">procurement software products</font> for use in     our Web-based <font color="blue">procurement product</font>, OmniBuyer</td>
    </tr>
    <tr>
      <td>If we <font color="blue">lose access</font> to, or the     ongoing  rights  to modify and distribute, these <font color="blue">technologies</font> with our     products we will either have to <font color="blue">devote resources</font> to <font color="blue">in<font color="blue">dependent</font></font>ly develop,     maintain and support the <font color="blue">technologies</font> ourselves or transition to another     vendor</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">in<font color="blue">dependent</font></font> <font color="blue">development</font>, maintenance or support of these     <font color="blue">technologies</font> by us or the transition to <font color="blue">alternative</font> <font color="blue">technologies</font> could be     costly, time consuming and <font color="blue">could delay</font> our <font color="blue">product releases</font> and upgrade     schedules</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could negatively</font> and <font color="blue">materially</font> affect our ability     to market, sell or distribute our products and in turn our business and     prospects</td>
    </tr>
    <tr>
      <td>Our international <font color="blue">operations</font> may subject us to <font color="blue">additional</font> risks that can     <font color="blue">adversely</font> affect our operating results</td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">operations</font> outside of the United States, consisting of     primarily software <font color="blue">development</font> and <font color="blue">customer support</font>, and in the future we     may  expand  our  international <font color="blue">operations</font>, <font color="blue">particularly</font> in India</td>
    </tr>
    <tr>
      <td>Our     international <font color="blue">operations</font> introduce a variety of risks, including:       ·       the <font color="blue">difficult</font>y of managing an <font color="blue">organization</font> operating in various     countries;       ·       growing political sentiment against international outsourcing of     <font color="blue">support services</font> and <font color="blue">development</font>;       ·        reduced  protection  for <font color="blue">intellectual</font> property rights in some     countries       20     ______________________________________________________________________       ·       changes in regulatory <font color="blue"><font color="blue">requirement</font>s</font>;       ·       the <font color="blue">requirement</font> to <font color="blue">comply with</font> a variety of <font color="blue">international laws</font> and     <font color="blue">regulations</font>, including <font color="blue">local labor ordinances</font> and changes in <font color="blue">tariff rates</font>;       ·        <font color="blue">fluctuations</font>  in  <font color="blue">currency exchange rates</font> and <font color="blue">difficult</font>ies in     <font color="blue">transferring funds from certain countries</font>; and       ·       political unrest, terrorism and the potential for other <font color="blue">hostilities</font>     in areas in which we have <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font>, in part, on our ability to anticipate and address these     risks</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that these or other <font color="blue">factors will</font> not <font color="blue">adversely</font>     affect our business or operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>regulation of the <font color="blue">healthcare industry</font> could reduce demand for our     products</td>
    </tr>
    <tr>
      <td>While the <font color="blue">manufacture</font> and sale of our current products are not regulated by     the <font color="blue">United States </font>Food and Drug Administration, or FDA, these products, or     our future products, if any, may be regulated in the future</td>
    </tr>
    <tr>
      <td>A <font color="blue">requirement</font>     for FDA <font color="blue">approval could reduce</font> the demand for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmacies </font>are     regulated  by individual state boards of pharmacy that <font color="blue">issue rules</font> for     pharmacy  licensure in their respective <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>State boards of     pharmacy do not license or approve our <font color="blue">medication</font> and <font color="blue">supply dispensing</font>     systems; however, pharmacies using our equipment are subject to state board     approval</td>
    </tr>
    <tr>
      <td>The failure of <font color="blue">such pharmacies</font> to meet differing <font color="blue"><font color="blue">requirement</font>s</font> from     a <font color="blue">significant</font> number of state boards of <font color="blue">pharmacy could decrease demand</font> for     our products and harm our <font color="blue"><font color="blue">competitive</font> position</font>, results of <font color="blue">operations</font> and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">hospitals must</font> be <font color="blue">accredited by</font> the Joint     Commission on Accreditation of Healthcare Organizations, or JCAHO, in order     to be eligible <font color="blue">for Medicaid and Medicare </font>funds</td>
    </tr>
    <tr>
      <td>JCAHO does not approve or     accredit <font color="blue">medication</font> and supply <font color="blue">dispensing systems</font>; however, disapproval of     our customers’ <font color="blue">medication</font> and <font color="blue">supply dispensing</font> <font color="blue">management</font> methods and their     failure to meet JCAHO <font color="blue"><font color="blue">requirement</font>s</font> could decrease demand for our products     and harm our <font color="blue"><font color="blue">competitive</font> position</font>, results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>While  we have implemented a <font color="blue">Privacy and Use of Information Policy </font>and     strictly  adhere  to  established  privacy principles, use of customer     information  <font color="blue">guidelines</font> and federal and state statutes and <font color="blue">regulations</font>     regarding privacy and <font color="blue">confidentiality</font>, we <font color="blue">cannot assure</font> you that we will be     in compliance with the Health Insurance Portability and Accountability Act     of 1996, <font color="blue">or HIPAA This </font><font color="blue">legislation</font> required the <font color="blue">Secretary of Health </font>and     Human  Services, or HHS, to adopt national standards for some types of     <font color="blue">electronic</font> health information <font color="blue"><font color="blue">transaction</font>s</font> and the <font color="blue">data elements used</font> in     those  <font color="blue"><font color="blue">transaction</font>s</font>,  to  adopt  standards to ensure the integrity and     <font color="blue">confidentiality</font>  of health information and to establish a schedule for     implementing national health data privacy <font color="blue">legislation</font> or <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In     August 2002, HHS published final <font color="blue">modification</font>s to its privacy <font color="blue">regulations</font>     that took effect on April 14, 2003</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> restrict the use and     <font color="blue">disclosure</font> of <font color="blue">personally identifiable health</font> information by our customers     who are ‘‘<font color="blue">covered entities</font>’’ under HIPAA Because Omnicell may be considered     a ‘‘business associate’’ under HIPAA, many of our customers have required     that  we <font color="blue">enter into written agreements governing</font> the way we handle any     patient information we <font color="blue">may encounter</font> in providing our products and services</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2003, HHS <font color="blue">issued final security rules</font> requiring <font color="blue">covered entities</font>     to implement <font color="blue">appropriate</font> technical and <font color="blue">physical safeguards</font> of <font color="blue">electronic</font>ally     <font color="blue">transmitted personal health</font> information by April 2005</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the     <font color="blue">potential impact</font> of these rules, rules that have not <font color="blue">yet been proposed</font> or     any  other  rules that might be <font color="blue">finally adopted on</font> our customers or on     Omnicell</td>
    </tr>
    <tr>
      <td>In addition, other federal and/or state privacy <font color="blue">legislation</font> may be     <font color="blue">enacted at</font> any time</td>
    </tr>
    <tr>
      <td>These laws and <font color="blue">regulations</font> could restrict the ability     of our customers to obtain, use or <font color="blue">disseminate patient</font> information</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>could  reduce  the demand for our products or force us to redesign our     products in order to meet regulatory <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>We adopted a <font color="blue">stockholder rights</font> plan that may discourage, delay or prevent a     merger or <font color="blue">acquisition</font> that is <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2003, our <font color="blue">Board of Directors </font>adopted a <font color="blue">stockholder rights</font> plan     that may have the effect of discouraging, delaying or preventing a change in     control of our company that is <font color="blue">beneficial</font> to our        21     ______________________________________________________________________       <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Pursuant to the terms of the plan, when a person or group,     <font color="blue">except under certain circumstances</font>, acquires 15prca or more of our outstanding     <font color="blue">common stock</font> (other than two current <font color="blue">stockholders</font> and their <font color="blue">affiliated</font>     entities,  which  will not trigger the rights plan unless they acquire     <font color="blue">beneficial</font>  ownership of 17dtta5prca and 22dtta5prca or more, <font color="blue">respectively</font>, of our     outstanding  common  stock) or ten business days after <font color="blue">commencement</font> or     <font color="blue">announcement</font>  of  a  tender  or  <font color="blue">exchange offer</font> for 15prca or more of our     outstanding <font color="blue">common stock</font>, the rights (except those rights held by the person     or group who has acquired or announced an offer to acquire 15prca or more of     our outstanding <font color="blue">common stock</font>) would <font color="blue">generally</font> become exercisable for shares     of our <font color="blue">common stock</font> at a discount</td>
    </tr>
    <tr>
      <td>Because the potential acquiror’s rights     would not become exercisable for our shares of <font color="blue">common stock</font> at a discount,     the potential acquiror would suffer substantial dilution and may lose its     ability to acquire us</td>
    </tr>
    <tr>
      <td>In addition, the existence of the plan <font color="blue">itself may</font>     deter  a  <font color="blue">potential acquiror from</font> acquiring us</td>
    </tr>
    <tr>
      <td>As a result, either by     operation of the plan or by its <font color="blue">potential deterrent</font> effect, a change in     control of our company that our <font color="blue">stockholders</font> may consider in their best     <font color="blue">interests may</font> not occur</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">facilities</font> are located near <font color="blue">known earthquake fault zones</font>, and the     occurrence  of  an  earthquake  or other <font color="blue">natural disaster</font> or any other     <font color="blue">catastrophic event could</font> cause damage to our <font color="blue">facilities</font> and equipment, which     could require us to cease or curtail <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">facilities</font>  are located near <font color="blue">known earthquake fault zones</font> and are     vulnerable to <font color="blue">significant</font> <font color="blue">damage from</font> earthquakes</td>
    </tr>
    <tr>
      <td>We are <font color="blue">also vulnerable</font> to     <font color="blue">damage from</font> other types of <font color="blue">disasters</font>, including fires, floods, power loss,     <font color="blue">communications failures</font> and similar events including the effects of war or     acts of terrorism</td>
    </tr>
    <tr>
      <td>If any disaster were to occur, our ability to operate our     business at our <font color="blue">facilities</font> could be seriously or <font color="blue">completely</font> impaired or     destroyed</td>
    </tr>
    <tr>
      <td>The insurance we maintain may not be adequate to cover our losses     resulting from <font color="blue">disasters</font> or other business <font color="blue">interruptions</font></td>
    </tr>
  </tbody>
</table>